Bimekizumab for Psoriatic Arthritis
Trial Summary
What is the purpose of this trial?
The purpose of the study is to compare the efficacy of bimekizumab versus risankizumab after 16 weeks of treatment in study participants with active psoriatic arthritis (PsA).
Will I have to stop taking my current medications?
The trial allows participants to continue taking certain medications like methotrexate, sulfasalazine, and NSAIDs, but you may need to stop other PsA medications if they don't meet the required washout period (time without taking certain medications) before the study starts. It's best to discuss your specific medications with the study team.
What data supports the effectiveness of the drug Bimekizumab for treating psoriatic arthritis?
Research shows that Bimekizumab, a drug that blocks certain proteins involved in inflammation, is more effective than a placebo in reducing symptoms of psoriatic arthritis, especially in patients who haven't used other similar treatments before. Studies also indicate that it remains effective and safe over a longer period, up to 52 weeks.12345
Is Bimekizumab safe for humans?
How is the drug Bimekizumab different from other treatments for psoriatic arthritis?
Research Team
UCB Cares
Principal Investigator
001 844 599 2273
Eligibility Criteria
This trial is for adults with active Psoriatic Arthritis diagnosed at least 6 months ago, who have not responded well to or tolerated previous treatments. Participants must have at least 3 tender and swollen joints and one psoriatic skin lesion or a history of plaque-type psoriasis.Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either bimekizumab or risankizumab for 16 weeks to evaluate efficacy and safety
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Bimekizumab
Bimekizumab is already approved in European Union, United States for the following indications:
- Moderate to severe plaque psoriasis
- Active psoriatic arthritis
- Non-radiographic axial spondyloarthritis
- Active ankylosing spondylitis
- Moderate-to-severe plaque psoriasis
- Active psoriatic arthritis
- Non-radiographic axial spondyloarthritis
- Active ankylosing spondylitis
- Hidradenitis suppurativa
Find a Clinic Near You
Who Is Running the Clinical Trial?
UCB Biopharma SRL
Lead Sponsor
Jean-Christophe Tellier
UCB Biopharma SRL
Chief Executive Officer since 2015
MD from University of Reims Champagne-Ardenne, Rheumatology specialization from University of Paris V, Executive business programs at Harvard and INSEAD
Dr. Iris Loew-Friedrich
UCB Biopharma SRL
Chief Medical Officer since 2014
MD from University of Leuven, PhD in Medical Sciences from University of Leuven